Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00859053 · ClinicalTrials.gov registry record · Phase 1
Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment
A Phase 1 study of Hepatic Insufficiency, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 2
- Study locations
NCT00859053: Completed Phase 1 study of Hepatic Insufficiency, sponsored by Bristol-Myers Squibb.
NCT00859053 is a Phase 1 study of Hepatic Insufficiency that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 46 participants, above the 37-participant average among 14 other Hepatic Insufficiency trials with a reported enrollment target (24% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00859053, a Phase 1 study of Hepatic Insufficiency, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess the effects of hepatic impairment on the single dose pharmacokinetics of BMS-790052.
Primary Outcome
Maximum observed plasma concentration following drug administration from the raw plasma concentration-time data. The plasma samples were analysed for BMS-790052 by using a validated liquid chromatography tandem mass spectrometric (LC-MS/MS) assay.
Conditions Studied
Interventions
- DRUG BMS-790052
Study Locations (2)
California
- Advanced Clinical Research Institute - Anaheim
Florida
- Orlando Clinical Research Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2009-03 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
What the finished NCT00859053 record still lists
NCT00859053 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, above the 37-participant average among 14 other Hepatic Insufficiency trials with a reported enrollment target (24% higher).
The record links to 1 condition, with Hepatic Insufficiency appearing as the primary indexed condition, and to 1 intervention - of which BMS-790052 is the first listed.
NCT00859053 reports a single indexed study location in California, Florida.
Frequently Asked Questions
What is clinical trial NCT00859053 about?
NCT00859053 is a clinical study titled "Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment". The purpose of this study is to assess the effects of hepatic impairment on the single dose pharmacokinetics of BMS-790052.
What is the current status of trial NCT00859053?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2009-03. Estimated completion is 2009-09.
What conditions does trial NCT00859053 study?
This clinical trial studies the following conditions: Hepatic Insufficiency.
What interventions are being tested in trial NCT00859053?
The interventions under investigation include: BMS-790052 (DRUG).
Who is sponsoring clinical trial NCT00859053?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00859053 being conducted?
This trial has 2 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Insufficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00859053's enrollment target sits among peer trials
46 3rd of 14 higher than 11 of 14 other Hepatic Insufficiency trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatic Insufficiency trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
RECRUITING · Phase 1
-
A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.
RECRUITING · Phase 1
-
Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
COMPLETED · Phase 1
-
A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
COMPLETED · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia